What is EVerZom?
EVerZom is an innovative exosome biotech company focused on developing exosome therapeutics for digestive tissue healing, fistula treatment, and organ regeneration. Founded in 2019, the company aims to revolutionize the therapeutic landscape with its proprietary platform that encompasses the entire technological value chain of exosome production. EVerZom is currently advancing two drug candidates targeting Crohn's fistula and organ regeneration, with promising preclinical results indicating accelerated healing and reduced inflammation.
How much funding has EVerZom raised?
EVerZom has raised a total of $1.3M across 1 funding round:
Unspecified
$1.3M
Unspecified (2020): $1.3M, investors not publicly disclosed
What's next for EVerZom?
With this major enterprise-level funding, EVerZom is poised to accelerate its development pipeline, particularly its drug candidates for Crohn's fistula and organ regeneration. The company's strategic focus on a proprietary platform covering the full exosome production value chain positions it for significant growth. EVerZom seeks to establish partnerships for co-development in various therapeutic areas, aiming to address substantial unmet medical needs in the regenerative medicine sector and further solidify its market position.
See full EVerZom company page
